TrialJournal for immunotherapy of cancer2024
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
Danny Rischin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papercites it